ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.450
-0.150 (-5.77%)
At close: Feb 20, 2026, 4:00 PM EST
2.440
-0.010 (-0.41%)
After-hours: Feb 20, 2026, 7:17 PM EST
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
321.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.18M | -3.61M | -75.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 105.65M |
| Cellectis | 82.55M |
| XOMA Royalty | 47.11M |
| Fennec Pharmaceuticals | 38.79M |
| Armata Pharmaceuticals | 5.05M |
ALXO News
- 2 days ago - ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - GlobeNewsWire
- 2 days ago - ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - GlobeNewsWire
- 22 days ago - ALX Oncology Announces Pricing of Underwritten Offering - GlobeNewsWire
- 22 days ago - New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - GlobeNewsWire
- 5 weeks ago - ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - GlobeNewsWire
- 2 months ago - ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - GlobeNewsWire